Table 1.
Baseline characteristics of 57 patients with hepatocellular carcinoma.
Table 2.
Univariate and multivariate survival analyses according to pre-treatment factors.
Fig 1.
Cumulative overall survival according to modified RECIST.
The median overall survival was significantly shorter in the progressive disease (PD) group than in the partial response (PR) + stable disease (SD) group (134 days vs. 378 days; p<0.0001).
Fig 2.
Cumulative overall survival according to the changes in the intra-tumor blood flow.
The median overall survival was significantly shorter in the intra-tumor blood flow non-disappearance (non-DA) group than in the disappearance (DA) group (212 days vs. 341 days; p = 0.0204).
Fig 3.
Cumulative overall survival according to changes in alpha-fetoprotein level.
The median overall survival was significantly shorter in the high alpha-fetoprotein (AFP) ratio group than in the low AFP ratio group (170 days vs. 340 days; p = 0.0098).
Fig 4.
Cumulative overall survival according to changes in remnant liver function.
The median overall survival was significantly shorter in the liver function deterioration group than in the non-liver function deterioration group (96 days vs. 263 days; p = 0.0111).
Table 3.
Univariate and multivariate survival analyses according to on-treatment factors at 2 weeks after the start of sorafenib therapy.
Fig 5.
Cumulative overall survival in the poor prognostic score 0, 1, 2, 3, and 4 groups.
There were significant differences in the cumulative overall survival of patients among the five groups (p<0.0001).
Fig 6.
Cumulative overall survival in the poor prognostic score 4, 3 or 2 and 1 or 0 groups.
In the poor prognostic score 4, 3 or 2 groups, the median overall survival was significantly shorter than that in the poor prognostic score 1 or 0 groups (194 vs. 378 days; p = 0.0010).
Table 4.
Relationship between the each poor prognostic score at 2 weeks and the anti-tumor response by modified RECIST at 6 weeks.
Table 5.
Relationship between the two stratified poor prognostic score groups at 2 weeks and the anti-tumor response by modified RECIST at 6 weeks.